《Cancer》重点专注发布医学-肿瘤学领域的新研究，旨在促进和传播该领域相关的新技术和新知识。鼓励该领域研究者详细地发表他们的高质量实验研究和理论结果。根据网友分享的投稿经验，平均审稿速度为 很快,2-3周 。该杂志创刊至今，在医学-肿瘤学领域，影响力非凡，对来稿文章质量要求很高，稿件投稿过审难度很大，刊登文章的学术水平和编辑质量在同类杂志中均名列前茅。如果你想在该杂志上发表论文，你可以向编辑部提交文章，但文章必须具有重要意义并代表该领域专业的发展。我们欢迎广大同领域的研究者提交投稿。
| CiteScore | SJR | SNIP | CiteScore排名 | |||
|---|---|---|---|---|---|---|
| 13.1 | 2.887 | 2.021 | 学科类别 | 分区 | 排名 | 百分位 |
|
大类：大类：Medicine
小类：小类：Oncology
|
Q1 | 39/404 | 90% | |||
|
大类：大类：Medicine
小类：小类：CancerResearch
|
Q1 | 33/230 | 85% | |||
| 按JIF指标学科分区 | 收录子集 | 分区 | 排名 | 百分位 |
|---|---|---|---|---|
| 学科：ONCOLOGY | SCIE | Q1 | 49 / 322 | 84.9% |
| 按JCI指标学科分区 | 收录子集 | 分区 | 排名 | 百分位 |
|---|---|---|---|---|
| 学科：ONCOLOGY | SCIE | Q1 | 54 / 322 | 83.39% |
文章名称
引用次数
Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics
228
High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma
68
Targeting Autophagy in Cancer
59
Analytical Performance of the ThyroSeq v3 Genomic Classifier for Cancer Diagnosis in Thyroid Nodules
52
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study
50
Comparison of the Toxicity Profile of PD-1 Versus PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Analysis of the Literature
43
Targeting autophagy using natural compounds for cancer prevention and therapy
43
Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics
40
Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial
35
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia
35
国家/地区
发文量
TUSA
1512
TCanada
185
TCHINA MAINLAND
111
TEngland
92
TGERMANY (FED REP GER)
92
TItaly
92
TFrance
77
TNetherlands
66
TJapan
55
TAustralia
50
